Dataset Information

Biochemical and molecular study on serum miRNA-16a and miRNA- 451 as neonatal sepsis biomarkers.

ABSTRACT:

Background

Sepsis is the serious cause of fatality in the unit of medical-intensive care (ICU). Non-coding RNA transcripts are microRNA that control gene expression by repressing translation or degrading mRNA. There are several reports discussing the concept of using miRNAs as sepsis a biomarkers by profiling miRNA dysregulation in sepsis patients' blood samples.

Objectives

The research was aimed at exploring the clinical utility of miRNA-16a and miRNA- 451 for diagnosis of neonatal sepsis.

Subjects

and methods: This research was conducted on 50 full term neonates, 25 neonates with suspected or proven sepsis and 25 clinically healthy sex and age matched neonates with no evidence of sepsis. All newborns have been exposed to clinical review, history taking and laboratory investigations including total & differential count of blood cells, C-reactive protein, blood culture. Serum miRNA-16a and miRNA-451 levels have been assessed using Real Time polymerase chain reaction (Real Time PCR) technique.

Results

Neonates with sepsis had considerably higher levels of miRNA-16a and miRNA- 451 than the healthy neonates (p ? 0.001). Receiver operating curve (ROC) showed that serum miRNA-16a was superior to miRNA-451 for diagnosis of sepsis with neonatal origin; it had sensitivity and specificity of 88% and 98% versus 64% and 61% respectively. Cut off point for miRNA-16a to diagnose neonatal sepsis was above or equal 3.16. Also, cut off point for miRNA-451 was above or equal 1.26. miRNA-16 a and miRNA 451 expression was significantly correlated with respiratory rate, WBCs, and CRP.

Conclusion

Both miRNA -16a and miRNA-451 are detected in higher levels in newborn with sepsis compared to controls. MiRNA- 16a could be considered as promising biomarkers for diagnosis of neonatal sepsis.

SUBMITTER: El-Hefnawy SM

PROVIDER: S-EPMC7815658 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Biochemical and molecular study on serum miRNA-16a and miRNA- 451 as neonatal sepsis biomarkers.

El-Hefnawy Sally M SM Mostafa Rasha G RG El Zayat Rania S RS Elfeshawy Esraa M EM Abd El-Bari Hamed M HM El-Monem Ellaithy Manal Abd MA

Biochemistry and biophysics reports 20210116

<h4>Background</h4>Sepsis is the serious cause of fatality in the unit of medical-intensive care (ICU). Non-coding RNA transcripts are microRNA that control gene expression by repressing translation or degrading mRNA. There are several reports discussing the concept of using miRNAs as sepsis a biomarkers by profiling miRNA dysregulation in sepsis patients' blood samples.<h4>Objectives</h4>The research was aimed at exploring the clinical utility of miRNA-16a and miRNA- 451 for diagnosis of neonat ...[more]

PMID: 33506118

Similar Datasets

Project description:Introduction Diagnosing neonatal sepsis is heavily dependent on clinical phenotyping as culture-positive body fluid has poor sensitivity, and existing blood biomarkers have poor specificity. A combination of machine learning, statistical and deep pathway biology analyses led to the identification of a tripartite panel of biologically connected immune and metabolic markers that showed greater than 99% accuracy for detecting bacterial infection with 100% sensitivity. The cohort study described here is designed as a large-scale clinical validation of this previous work. Methods and analysis This multicentre observational study will prospectively recruit a total of 1445 newborn infants (all gestations)—1084 with suspected early—or late-onset sepsis, and 361 controls—over 4 years. A small volume of whole blood will be collected from infants with suspected sepsis at the time of presentation. This sample will be used for integrated transcriptomic, lipidomic and targeted proteomics profiling. In addition, a subset of samples will be subjected to cellular phenotype and proteomic analyses. A second sample from the same patient will be collected at 24 hours, with an opportunistic sampling for stool culture. For control infants, only one set of blood and stool sample will be collected to coincide with clinical blood sampling. Along with detailed clinical information, blood and stool samples will be analysed and the information will be used to identify and validate the efficacy of immune-metabolic networks in the diagnosis of bacterial neonatal sepsis and to identify new host biomarkers for viral sepsis. Ethics and dissemination The study has received research ethics committee approval from the Wales Research Ethics Committee 2 (reference 19/WA/0008) and operational approval from Health and Care Research Wales. Submission of study results for publication will involve making available all anonymised primary and processed data on public repository sites. Trial registration number NCT03777670

Dataset Information

Biochemical and molecular study on serum miRNA-16a and miRNA- 451 as neonatal sepsis biomarkers.

Background

Objectives

Subjects

Results

Conclusion

Publications

Biochemical and molecular study on serum miRNA-16a and miRNA- 451 as neonatal sepsis biomarkers.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets